IL144043A0 - Reovirus for the treatment of cellular proliferative disorders - Google Patents

Reovirus for the treatment of cellular proliferative disorders

Info

Publication number
IL144043A0
IL144043A0 IL14404300A IL14404300A IL144043A0 IL 144043 A0 IL144043 A0 IL 144043A0 IL 14404300 A IL14404300 A IL 14404300A IL 14404300 A IL14404300 A IL 14404300A IL 144043 A0 IL144043 A0 IL 144043A0
Authority
IL
Israel
Prior art keywords
reovirus
treatment
proliferative disorders
cellular proliferative
cellular
Prior art date
Application number
IL14404300A
Other languages
English (en)
Original Assignee
Oncolytics Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncolytics Biotech Inc filed Critical Oncolytics Biotech Inc
Publication of IL144043A0 publication Critical patent/IL144043A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/765—Reovirus; Rotavirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011—Details
    • C12N2720/12011—Reoviridae
    • C12N2720/12032—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011—Details
    • C12N2720/12011—Reoviridae
    • C12N2720/12211—Orthoreovirus, e.g. mammalian orthoreovirus
    • C12N2720/12232—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
IL14404300A 1999-02-24 2000-02-18 Reovirus for the treatment of cellular proliferative disorders IL144043A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/256,824 US6136307A (en) 1997-08-13 1999-02-24 Reovirus for the treatment of cellular proliferative disorders
PCT/CA2000/000178 WO2000050051A2 (en) 1999-02-24 2000-02-18 Reovirus for the treatment of cellular proliferative disorders

Publications (1)

Publication Number Publication Date
IL144043A0 true IL144043A0 (en) 2002-04-21

Family

ID=22973731

Family Applications (3)

Application Number Title Priority Date Filing Date
IL14404300A IL144043A0 (en) 1999-02-24 2000-02-18 Reovirus for the treatment of cellular proliferative disorders
IL144043A IL144043A (en) 1999-02-24 2001-06-28 Use of reovirus for the preparation of a pharmaceutical composition for the treatment of cellular proliferative disorders
IL197903A IL197903A (en) 1999-02-24 2009-04-05 A pharmacovigilance containing riavirus to treat cell culture disorders and its kit

Family Applications After (2)

Application Number Title Priority Date Filing Date
IL144043A IL144043A (en) 1999-02-24 2001-06-28 Use of reovirus for the preparation of a pharmaceutical composition for the treatment of cellular proliferative disorders
IL197903A IL197903A (en) 1999-02-24 2009-04-05 A pharmacovigilance containing riavirus to treat cell culture disorders and its kit

Country Status (17)

Country Link
US (8) US6136307A (es)
EP (2) EP1156813B1 (es)
JP (1) JP2002537344A (es)
AR (1) AR022734A1 (es)
AT (1) ATE400283T1 (es)
AU (1) AU776401C (es)
CA (1) CA2360833C (es)
DE (1) DE60039415D1 (es)
DK (1) DK1156813T3 (es)
ES (1) ES2308971T3 (es)
HK (1) HK1039752B (es)
IL (3) IL144043A0 (es)
MX (1) MXPA01008457A (es)
NZ (2) NZ512661A (es)
PT (1) PT1156813E (es)
TW (1) TWI290467B (es)
WO (1) WO2000050051A2 (es)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6136307A (en) * 1997-08-13 2000-10-24 Oncolytics Biotech Inc. Reovirus for the treatment of cellular proliferative disorders
US6565831B1 (en) * 1999-02-24 2003-05-20 Oncolytics Biotech Inc. Methods for preventing reovirus recognition for the treatment of cellular proliferative disorders
US6110461A (en) * 1997-08-13 2000-08-29 Oncolytics Biotech Inc. Reovirus for the treatment of neoplasia
US7780962B2 (en) * 1997-10-09 2010-08-24 Wellstat Biologics Corporation Treatment of neoplasms with RNA viruses
US20030044384A1 (en) * 1997-10-09 2003-03-06 Pro-Virus, Inc. Treatment of neoplasms with viruses
HUP0302278A3 (en) * 1999-04-15 2011-01-28 Pro Virus Treatment of neoplasms with viruses
US8147822B1 (en) * 1999-09-17 2012-04-03 Wellstat Biologics Corporation Oncolytic virus
EP1955703A1 (en) * 1999-11-12 2008-08-13 Oncolytics Biotech Inc. Viruses for the treatment of cellular proliferative disorders
AUPQ425699A0 (en) 1999-11-25 1999-12-23 University Of Newcastle Research Associates Limited, The A method of treating a malignancy in a subject and a pharmaceutical composition for use in same
US7306902B2 (en) * 2002-06-28 2007-12-11 Oncolyties Biotech Inc. Oncolytic viruses as phenotyping agents for neoplasms
US8491884B2 (en) 2000-05-03 2013-07-23 Oncolytics Biotech Inc. Virus clearance of neoplastic cells from mixed cellular compositions
AR028040A1 (es) 2000-05-03 2003-04-23 Oncolytics Biotech Inc Remocion de virus de celulas neoplasticas a partir de composiciones celulares mixtas
AR028039A1 (es) 2000-05-03 2003-04-23 Oncolytics Biotech Inc Remocion de reovirus de celulas neoplasticas intermediadas por ras a partir de composiciones celulares mixtas
CN1250711C (zh) * 2000-06-26 2006-04-12 威尔斯达特生物制剂公司 用病毒清除细胞
TWI289158B (en) * 2000-08-10 2007-11-01 Oncolytics Biotech Inc Method of producing infectious reovirus
JP4146725B2 (ja) 2000-11-09 2008-09-10 オンコリティクス バイオテク，インコーポレーテッド 細胞増殖性障害の処置のための方法
BR0115127A (pt) * 2000-11-20 2004-02-17 Oncolytics Biotech Inc Método de fornecer um vìrus a um tumor sólido para reduzir crescimento do tumor
AU2002220416A1 (en) * 2000-12-01 2002-06-11 University Of Ottawa Oncolytic virus
AR035227A1 (es) * 2001-02-20 2004-05-05 Oncolytics Biotech Inc Uso de un agente quimioterapeutico para la manufactura de un medicamento para la sensibilizacion de celulas neoplasicas resistentes a agentes quimioterapeuticos con reovirus
WO2003011230A2 (en) * 2001-08-03 2003-02-13 Board Of Regents, The University Of Texas System Modified reoviral therapy
US20040115170A1 (en) * 2001-11-30 2004-06-17 Brown Earl Garnet Oncolytic virus
CA2374388C (en) 2002-02-28 2005-07-12 Matthew C. Coffey The use of ribozymes in the detection of adventitious agents
US20040005546A1 (en) * 2002-02-28 2004-01-08 Oncolytics Biotech Inc. Use of ribozymes in the detection of adventitious agents
EP1944035A1 (en) 2002-05-09 2008-07-16 Oncolytics Biotech Inc. Method for reducing pain using oncolytic viruses
BR0309825A (pt) * 2002-05-09 2005-03-01 Oncolytics Biotech Inc Método e composição farmacêutica para reduzir a dor em um mamìfero que sofra de um neoplasma
CA2482826C (en) * 2002-05-10 2011-11-22 Oncolytics Biotech Inc. Sensitization of neoplastic cells to radiation therapy with oncolytic viruses
US7163678B2 (en) * 2002-11-07 2007-01-16 Oncolytics Biotech Inc. Reovirus for the treatment of ral-mediated cellular proliferative disorders
AU2002953436A0 (en) * 2002-12-18 2003-01-09 The University Of Newcastle Research Associates Limited A method of treating a malignancy in a subject via direct picornaviral-mediated oncolysis
CA2522711A1 (en) * 2003-04-25 2004-11-11 Wellstat Biologics Corporation Treating hepatocellular carcinomas using therapeutic viruses
SG179291A1 (en) 2003-06-18 2012-04-27 Genelux Corp Modified recombinant vaccinia viruses and other microorganisms, uses thereof
US20050019308A1 (en) * 2003-07-07 2005-01-27 Oncolytics Biotech Inc. Oncolytic viruses for the treatment of neoplasms having activated PP2A or Rac
US20050137152A1 (en) * 2003-12-19 2005-06-23 Danny Cheung Reovirus for the prevention of neoplasia
US20050214266A1 (en) * 2004-03-12 2005-09-29 Oncolytics Biotech Inc. Combination of transplantation and oncolytic virus treatment
WO2005112966A1 (en) * 2004-05-21 2005-12-01 Orison Biotechnology Inc. Combined therapy with a herbal extract and a reovirus for killing neoplastic cells in a subject
US7901921B2 (en) * 2004-10-22 2011-03-08 Oncolytics Biotech Inc. Viral purification methods
CA2617600A1 (en) * 2005-08-01 2007-09-07 University Technologies International, Inc. Attenuated reovirus
US10668119B2 (en) 2005-08-01 2020-06-02 Virocure, Inc. Attenuated reovirus
US7828978B2 (en) * 2006-01-11 2010-11-09 Doug Geier Simultaneous synthesis and purification of a fatty acid monoester biodiesel fuel
DK1984007T3 (en) * 2006-02-13 2015-12-07 Oncolytics Biotech Inc Application of Low-dose local immunosuppression for amplification of viral oncolytic therapy
US20090098529A1 (en) 2006-10-16 2009-04-16 Nanhai Chen Methods for attenuating virus strains for diagnostic and therapeutic uses
MX2009009598A (es) * 2007-03-12 2009-09-21 Oncolytics Biotech Inc Reovirus que tienen secuencias modificadas.
US10369171B2 (en) 2007-03-13 2019-08-06 Virocure, Inc. Attenuated reoviruses for selection of cell populations
TW200909581A (en) * 2007-05-21 2009-03-01 Oncolytics Biotech Inc Mutant reoviruses and methods of making and using
WO2009011924A1 (en) * 2007-07-18 2009-01-22 Genelux Corporation Use of a chemotherapeutic agent in the preparation of a medicament for treating or ameliorating an adverse side effect associated with oncolytic viral therapy
CN101820892A (zh) * 2007-10-22 2010-09-01 昂科利蒂克斯生物科技公司 增殖性疾病的治疗方案
US20120052003A9 (en) * 2008-05-16 2012-03-01 Szalay Aladar A Microorganisms for preventing and treating neoplasms accompanying cellular therapy
WO2009143610A1 (en) * 2008-05-27 2009-12-03 Oncolytics Biotech Inc. Modulating interstitial pressure and oncolytic viral delivery and distribution
TW200950777A (en) * 2008-05-27 2009-12-16 Oncolytics Biotech Inc Abrogating proinflammatory cytokine production during oncolytic reovirus therapy
WO2012142529A2 (en) 2011-04-15 2012-10-18 Genelux Corporation Clonal strains of attenuated vaccinia viruses and methods of use thereof
WO2013163724A1 (en) * 2012-04-30 2013-11-07 Oncolytics Biotech Inc. Protecting modified viruses from neutralizing antibodies using the reovirus sigma 1 protein
EP3068411B1 (en) 2013-11-15 2020-03-18 Oncolytics Biotech Inc. Oncolytic viruses and increased cancer treatment regimens
EP3209382B1 (en) 2014-10-24 2020-11-25 Calidi Biotherapeutics, Inc. Combination immunotherapy approach for treatment of cancer
US11077157B2 (en) 2016-02-16 2021-08-03 Osaka University Medicinal composition for treating fibrosis
WO2020148422A1 (en) 2019-01-18 2020-07-23 Université Catholique de Louvain Virus compositions

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4108983A (en) * 1976-06-01 1978-08-22 The Wistar Institute Viral oncolysate vaccine for stimulating the immune mechanism of mammals to species-specific tumors
PT70556A (en) 1978-12-20 1980-01-01 Gist Brocades Nv Vaccines against diseases caused by reo-virus and process for the preparation of those vaccines
NL7812359A (nl) * 1978-12-20 1980-06-24 Gist Brocades Nv Vaccins tegen door reo virus veroorzaakte ziektever- schijnselen en werkwijze voor het bereiden van deze vaccins.
US4490358A (en) * 1982-03-01 1984-12-25 President And Fellows Of Harvard College Screening vaccines and immunization process
US4559229A (en) 1982-07-20 1985-12-17 Research Foundation Avian proventriculitis vaccine
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
JPS6255079A (ja) 1986-04-23 1987-03-10 Mihama Hisaharu 修飾ウリカ−ゼ
WO1990009441A1 (en) * 1989-02-01 1990-08-23 The General Hospital Corporation Herpes simplex virus type i expression vector
AU5275290A (en) * 1989-04-11 1990-11-05 Board Of Regents, The University Of Texas System Antitumor preparation obtained following oncolysate treatment
CA2039921A1 (en) * 1990-04-16 1991-10-17 Xandra O. Breakefield Transfer and expression of gene sequences into central nervous system cells using herpes simplex virus mutants with deletions in genes for viral replication
CA2051289C (en) * 1990-09-14 2002-11-26 Robert L. Martuza Viral mediated destruction of neoplastic cells
DK0931830T3 (da) * 1993-02-16 2001-06-11 Onyx Pharma Inc Cytopatiske vira til terapi og profylakse af neoplasi
US5525342A (en) 1994-05-20 1996-06-11 Akzo Nobel, N.V. Reovirus strain 2177 and vaccine containing same
US5614403A (en) * 1994-06-01 1997-03-25 Baylor College Of Medicine In vitro replication system capable of rescuing cloned and manipulated rotavirus genes
US5874531A (en) * 1995-03-07 1999-02-23 President And Fellows Of Harvard College Identification of self and non-self antigens implicated autoimmune disease
US5853716A (en) * 1995-07-28 1998-12-29 Yale University Genetically engineered chimeric viruses for the treatment of diseases associated with viral transactivators
TW349948B (en) * 1995-10-31 1999-01-11 Janssen Pharmaceutica Nv Farnesyl transferase inhibiting 2-quinolone derivatives
WO1998008541A1 (en) * 1996-08-30 1998-03-05 Genzyme Corporation Inhibition of primary and/or secondary immune response to repeat adenoviral vector administration using cd40l specific antibodies
US6110461A (en) * 1997-08-13 2000-08-29 Oncolytics Biotech Inc. Reovirus for the treatment of neoplasia
US6136307A (en) * 1997-08-13 2000-10-24 Oncolytics Biotech Inc. Reovirus for the treatment of cellular proliferative disorders
US6565831B1 (en) * 1999-02-24 2003-05-20 Oncolytics Biotech Inc. Methods for preventing reovirus recognition for the treatment of cellular proliferative disorders
ATE371372T1 (de) 1997-10-09 2007-09-15 Wellstat Biologics Corp Behandlung von neoplasmen mit interferon- empfindlichen, klonalen viren
AR028039A1 (es) * 2000-05-03 2003-04-23 Oncolytics Biotech Inc Remocion de reovirus de celulas neoplasticas intermediadas por ras a partir de composiciones celulares mixtas
AR035227A1 (es) * 2001-02-20 2004-05-05 Oncolytics Biotech Inc Uso de un agente quimioterapeutico para la manufactura de un medicamento para la sensibilizacion de celulas neoplasicas resistentes a agentes quimioterapeuticos con reovirus
CA2482826C (en) * 2002-05-10 2011-11-22 Oncolytics Biotech Inc. Sensitization of neoplastic cells to radiation therapy with oncolytic viruses
US7163678B2 (en) * 2002-11-07 2007-01-16 Oncolytics Biotech Inc. Reovirus for the treatment of ral-mediated cellular proliferative disorders
CA2621127C (en) * 2005-08-31 2014-02-25 Oncolytics Biotech Inc. Treatment with an oncolytic virus and an immunostimulant for in vivo enhancement of immune system recognition of neoplasms
MX2009009598A (es) * 2007-03-12 2009-09-21 Oncolytics Biotech Inc Reovirus que tienen secuencias modificadas.

Also Published As

Publication number Publication date
NZ512661A (en) 2004-04-30
US20090117082A1 (en) 2009-05-07
US8066985B2 (en) 2011-11-29
AU776401B2 (en) 2004-09-09
WO2000050051A2 (en) 2000-08-31
US6136307A (en) 2000-10-24
AU776401C (en) 2005-04-28
WO2000050051A3 (en) 2000-12-28
US20050063954A1 (en) 2005-03-24
EP1156813A2 (en) 2001-11-28
HK1039752B (zh) 2008-11-21
US8709443B2 (en) 2014-04-29
IL197903A (en) 2014-02-27
HK1039752A1 (en) 2002-05-10
ES2308971T3 (es) 2008-12-16
IL144043A (en) 2009-12-24
CA2360833C (en) 2008-05-13
NZ529362A (en) 2005-03-24
AU2788100A (en) 2000-09-14
US20030003080A1 (en) 2003-01-02
AR022734A1 (es) 2002-09-04
US8071087B2 (en) 2011-12-06
US7374752B2 (en) 2008-05-20
EP1156813B1 (en) 2008-07-09
DK1156813T3 (da) 2008-10-13
US20120141426A1 (en) 2012-06-07
DE60039415D1 (de) 2008-08-21
US6811775B2 (en) 2004-11-02
MXPA01008457A (es) 2002-06-21
EP1949905A1 (en) 2008-07-30
PT1156813E (pt) 2008-09-02
TWI290467B (en) 2007-12-01
JP2002537344A (ja) 2002-11-05
US20080026048A1 (en) 2008-01-31
ATE400283T1 (de) 2008-07-15
US6455038B1 (en) 2002-09-24
CA2360833A1 (en) 2000-08-31
US20110014155A1 (en) 2011-01-20

Similar Documents

Publication Publication Date Title
IL144043A0 (en) Reovirus for the treatment of cellular proliferative disorders
HK1047698A1 (zh) 用以治療細胞增生失調的病毒
HK1142833A1 (en) Methods for the treatment of cellular proliferative disorders
IL153846A0 (en) Methods for preventing reovirus recognition for the treatment of cellular proliferative disorders
HK1048073A1 (en) Use of xenon for treating neurointoxications.
AU6048201A (en) Quinazoline derivatives for the treatment of tumours
IL142950A0 (en) Device for the treatment of macular degeneration
ZA200109073B (en) Compositions for treatment of disorders of the oesophagus.
IL151890A0 (en) Hydroxyphenyl-piperidin 4-ylidene-methyl-benzamide derivatives for the treatment of pain
IL148579A0 (en) Oncolytic combinations for the treatment of cancer
EP1442062A4 (en) METHOD FOR TREATING CARCINOMA
EP1207874A4 (en) METHOD FOR THE TREATMENT OF PROLIFERATIVE DISEASES
HUP0200738A3 (en) Method of the treatment of incontinence
AU8322401A (en) Indole compounds useful for the treatment of cancer
HK1051692A1 (en) Quinolinyl-piperidin-4-ylidene-methyl-benzamide derivatives for the treatment of pain.
IL151765A0 (en) Hydroxyphenyl-piperazinyl-methyl-benzamide derivatives for the treatment of pain
GB0000113D0 (en) The use of triazolo-pyridazine derivatives for treating premenstrual syndrome
CZ20011872A3 (cs) Isonipekotamidy pro léčbu onemocnění zprostředkovaných integriny
HRP20020262A2 (en) Substituted pyrroles as antiproliferative agents for the treatment of cancer
HK1043938A1 (en) Composition for the treatment of psoriasis
HK1042039A1 (en) Use of phanquinone for the treatment or preventionof memory impairment.
EP1440160A4 (en) METHOD AND COMPOSITIONS FOR THE TREATMENT AND DIAGNOSIS OF CELL PROBLEMS UNDER THE USE OF 32222
SI1150704T1 (sl) Melagatran za zdravljenje vnetja
SI1224181T1 (en) Substituted pyrroles as antiproliferative agents for the treatment of cancer

Legal Events

Date Code Title Description
HC Change of name of proprietor(s)